William John Sibold sold $6.2M of MDGL
President and CEO at MADRIGAL PHARMACEUTICALS, INC.. 11,583 shares at an average of $538.65, traded Sep 9, 2026, filed Sep 11, 2026.
Score components
- +25RoleCEO
- +25Trade size$6.2M at market
- 0Share of holdings soldSold 5.5% of holdings
- 0ClusterNo other insider selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001628280-26-061581, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 9, 2026 | SOpen-market sale Common Stock10b5-1 | -131 | $527.88 | $69k | 209,198 | 32 d ago |
| Sep 9, 2026 | SOpen-market sale Common Stock10b5-1 | -347 | $529.27 | $184k | 208,851 | 32 d ago |
| Sep 9, 2026 | SOpen-market sale Common Stock10b5-1 | -522 | $530.23 | $277k | 208,329 | 32 d ago |
| Sep 9, 2026 | SOpen-market sale Common Stock10b5-1 | -368 | $531.99 | $196k | 207,961 | 32 d ago |
| Sep 9, 2026 | SOpen-market sale Common Stock10b5-1 | -512 | $533.09 | $273k | 207,449 | 32 d ago |
| Sep 9, 2026 | SOpen-market sale Common Stock10b5-1 | -396 | $534.20 | $212k | 207,053 | 32 d ago |
| Sep 9, 2026 | SOpen-market sale Common Stock10b5-1 | -644 | $535.27 | $345k | 206,409 | 32 d ago |
| Sep 9, 2026 | SOpen-market sale Common Stock10b5-1 | -1,040 | $536.11 | $558k | 205,369 | 32 d ago |
| Sep 9, 2026 | SOpen-market sale Common Stock10b5-1 | -640 | $537.17 | $344k | 204,729 | 32 d ago |
| Sep 9, 2026 | SOpen-market sale Common Stock10b5-1 | -520 | $538.30 | $280k | 204,209 | 32 d ago |
| Sep 9, 2026 | SOpen-market sale Common Stock10b5-1 | -215 | $539.03 | $116k | 203,994 | 32 d ago |
| Sep 9, 2026 | SOpen-market sale Common Stock10b5-1 | -505 | $540.19 | $273k | 203,489 | 32 d ago |
| Sep 9, 2026 | SOpen-market sale Common Stock10b5-1 | -362 | $541.65 | $196k | 203,127 | 32 d ago |
| Sep 9, 2026 | SOpen-market sale Common Stock10b5-1 | -160 | $542.55 | $87k | 202,967 | 32 d ago |
| Sep 11, 2026 | SOpen-market sale Common Stock10b5-1 | -60 | $533.09 | $32k | 202,907 | 32 d ago |
| Sep 11, 2026 | SOpen-market sale Common Stock10b5-1 | -106 | $534.06 | $57k | 202,801 | 32 d ago |
| Sep 11, 2026 | SOpen-market sale Common Stock10b5-1 | -218 | $535.94 | $117k | 202,583 | 32 d ago |
| Sep 11, 2026 | SOpen-market sale Common Stock10b5-1 | -160 | $537.62 | $86k | 202,423 | 32 d ago |
| Sep 11, 2026 | SOpen-market sale Common Stock10b5-1 | -687 | $540.59 | $371k | 201,736 | 32 d ago |
| Sep 11, 2026 | SOpen-market sale Common Stock10b5-1 | -368 | $541.64 | $199k | 201,368 | 32 d ago |
| Sep 11, 2026 | SOpen-market sale Common Stock10b5-1 | -1,202 | $542.60 | $652k | 200,166 | 32 d ago |
| Sep 11, 2026 | SOpen-market sale Common Stock10b5-1 | -1,539 | $544.02 | $837k | 198,627 | 32 d ago |
| Sep 11, 2026 | SOpen-market sale Common Stock10b5-1 | -761 | $544.83 | $415k | 197,866 | 32 d ago |
| Sep 11, 2026 | SOpen-market sale Common Stock10b5-1 | -120 | $546.38 | $66k | 197,746 | 32 d ago |
Related signals
Other insiders at MADRIGAL PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 45Moderate | MADRIGAL PHARMACEUTICALS, INC. | Mardi Dier EVP and CFO | $854k 1,982 shares | -14% | |
| 42Moderate | MADRIGAL PHARMACEUTICALS, INC. | Carole Huntsman Chief Commercial Officer | $181k 419 shares | -3% | |
| 41Moderate | MADRIGAL PHARMACEUTICALS, INC. | Shannon T Kelley General Counsel | $155k 360 shares | -3% | |
| 42Moderate | MADRIGAL PHARMACEUTICALS, INC. | Rebecca Taub director | $212k 491 shares | -0% | |
| 61Notable | MADRIGAL PHARMACEUTICALS, INC. | William John Sibold President and CEO | $718k 1,663 shares | -1% | |
| 60Notable | MADRIGAL PHARMACEUTICALS, INC. | Mardi Dier EVP and CFO | $505k 1,183 shares | -11% | |
| 27Weak | MADRIGAL PHARMACEUTICALS, INC. | Carole Huntsman Chief Commercial Officer | $449k 910 shares | -9% | |
| 44Moderate | MADRIGAL PHARMACEUTICALS, INC. | Rebecca Taub director | $319k 647 shares | -0% | |
| 62Notable | MADRIGAL PHARMACEUTICALS, INC. | William John Sibold President and CEO | $777k 1,577 shares | -1% | |
| 25Weak | MADRIGAL PHARMACEUTICALS, INC. | Shannon T Kelley General Counsel | $344k 692 shares | -8% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.